174258-63-0

Basic information

• Product Name: 1-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-yl]ethanone
• Synonyms: 1-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-yl]ethanone
• CAS NO: 174258-63-0
• Molecular Weight: 331.371
• Mol File: 174258-63-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-yl]ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-yl]ethanone(174258-63-0)
• EPA Substance Registry System: 1-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-yl]ethanone(174258-63-0)

Safety Data

• Hazardous Substances Data: 174258-63-0(Hazardous Substances Data)

Upstream product

• 174258-62-9 1-[2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-yl]ethanol 
• 1761-61-1 5-bromosalicyclaldehyde 
• 132646-33-4 2-<(5-methyl-2-phenyl-4-oxazolyl)methyl>benzofuran-5-carbonitrile 
• 132672-20-9 5-bromo-α-(5-methyl-2-phenyloxazol-4-yl)-2-benzofuranmethanol 
• 132646-31-2 (5-bromo-2-benzofuranyl)(5-methyl-2-phenyl-4-oxazolyl)methanone 
• 132646-34-5 2-(5-methyl-2-phenyl-4-oxazolyl)methyl-5-benzofurancarboxaldehyde 
• 132646-32-3 2-[(2-Phenyl-5-methyloxazol-4-yl)methyl]-5-bromobenzofuran 
• 103788-62-1 4-bromoacetyl-5-methyl-2-phenyl-oxazole 

Relevant articles and documents

Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones

A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated as oral antihyperglycemic agents in the obese insulin resistant db/db and ob/ob mouse - the two models for Type 2 diabetes mellitus. The majority of the prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-diones normalized plasma glucose levels at the 100 mg kg-1 oral dose in the db/db diabetic mouse model, and several amongst them reduced the glucose levels at the 20 mg kg-1 oral dose. The most potent compounds in the db/db mouse model were also active in the ob/ob mouse model normalizing the plasma glucose levels at the 20 mg kg-1 oral dose. The trifluoromethoxy analog 32 was the most active compound of the series, reducing significantly the plasma glucose levels at the 5 mg kg-1 oral dose. Oxadiazole-tailed 1,2,4-oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diabetic mouse models normalizing plasma glucose levels at the 100 mg kg-1 oral dose.

New azolidinediones and thiadiazolidinediones as antihyperglycemic agents

This invention relates to novel compounds which have demonstrated oral antihyperglycemic activity in diabetic ob/ob and db/db mice, animal models on non-insulin dependent diabetes mellitus (NIDDM ot Type II diabetes). These compounds have the formula: STR1 wherein: R1 is C1 -C6 alkyl, C3 -C8 cycloalkyl, thienyl, furyl, pyridyl, STR2 where R10 is hydrogen, C1 -C6 alkyl, fluorine, chlorine, bromine, iodine, C1 -C6 alkyoxy, trifluoroalkyl or trifluoroalkoxy; R2 is hydrogen or C1 -C6 alkyl; X is O or S; n is 0, 1, or 2; A is STR3 where R3 is hydrogen, C1 -C6 alkyl, halogen, C1 -C6 alkoxy, trifluoroalkyl or trifluoroalkoxy; B is STR4 where R4 is hydrogen, C1 -C6 alkyl, allyl, C6 -C10 aryl, C6 -C10 aryl-(CH2)1-6 --, fluorine, chlorine, bromine, iodine, trimethylsilyl or C3 -C8 cycloalkyl; R5 is hydrogen, C1 -C6 alkyl, C6 -C10 aryl, or C6 -C10 aryl-(CH2)1-6 --; m is 0, 1, or 2; R6 is hydrogen or C1 -C6 alkyl; R7 is hydrogen or C1 -C6 alkyl; R8 and R9 are selected independently from hydrogen, C1 -C6 alkyl, fluorine, chlorine, bromine, or iodine; Y is S; Z is N or CH; or a pharmaceutically acceptable salt thereof.